Clinical trial · Interventional
Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma
NCT07579507CI-TRIAL-00111262HOPESnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Potentially Malignant Disorder | Head and Neck Squamous Cell Carcinoma | PROBABILISTIC | 0.70 |
| Oral Squamous Cell Carcinomas | Oral Cavity Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen | Procedure | — | UNRESOLVED |
| Blood sampling | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- OSCC clinical-biological cohort
- description
- A clinical-biological cohort of 50 patients with OSCC. Blood sample and biospecimen at the time of a standard surgery.
- interventionNames
- Procedure: Biospecimen
- Procedure: Blood sampling
- type
- OTHER
- label
- OPMD clinical-biological cohort
- description
- A clinical-biological cohort of 50 patients with OPMD. Biospecimen at the time of a standard care.
- interventionNames
- Procedure: Biospecimen
- type
- OTHER
- label
- Cyto-OPMD clinical-biological cohort
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * I1: Male or female at least 18 years old. * I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD. * I3: Patient who has agreed to participate in this research and sign consent. * I4: Patient affiliated to a medical insurance. * I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy) Exclusion Criteria: * NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment. * NI2: Pregnant or nursing woman. * NI3: Contraindication to general anesthesia. * NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...). * NI5: Patient under curatorial or guardianship or placed under the protection of justice.
References
Publications (0)
Data not yet available
No reference posted for this study.